Structured overview of analytical themes identified in the integrative synthesis.
| Analytical theme | Key findings | Bioethical principles implicated | Representative examples | Policy implications |
|---|---|---|---|---|
| 1. Innovation paradox and financial toxicity | Targeted therapy costs exceed 100,000–150,000 USD/year, representing 10–20× the regional GDP per capita; up to 62.5% of patients discontinue treatment prematurely due to cost; financial toxicity leads to catastrophic health expenditure, dose-rationing, and treatment abandonment | Distributive justice; non-maleficence; right to health | Trastuzumab, pertuzumab (HER2+ breast cancer); osimertinib (EGFR+ NSCLC); pembrolizumab (PD-L1+ solid tumors); imatinib (CML) | Tiered pricing models reflecting regional purchasing power; ESMO-MCBS-based prioritization; regional price negotiation treating Latin America as a unified economic bloc |
| 2. Infrastructure deficits and epistemic injustice | NGS available in as few as 9.4% of LMIC oncology centers; ~80% of genomic study participants are of European ancestry; admixed Latin American populations (Amerindian, African, European lineages) underrepresented in molecular databases; unstudied CYP450 variants risk unexpected toxicities | Non-maleficence; epistemic justice; scientific integrity | EGFR, ALK, BRAF, NTRK, MET exon 14, RET alterations undetected without local NGS; Eurocentric genomic databases misrepresent regional mutation profiles | Genomic sovereignty: development of regional reference databases; public investment in local NGS infrastructure; protection of Latin American genomic data from extractive research practices |
| 3. Research vulnerability and informed consent | Clinical trials function as survival strategies for patients lacking funded alternatives; therapeutic misconception compromises voluntariness of consent; consent forms written at post-graduate reading level; lack of PTA agreements constitutes biopiracy | Autonomy; justice; respect for persons; non-exploitation | Trials of tepotinib (MET exon 14), selpercatinib (RET fusions), entrectinib (NTRK fusions) with no publicly funded alternative; consent literacy gaps in indigenous communities regarding concepts of inheritance and illness | Mandatory pre-negotiated PTA agreements as condition for research approval; culturally adapted consent through community health mediators and dialogic consent processes; ethics committee reform toward active advocacy |
| 4. Judicialization dilemma | Court-ordered access to high-cost drugs bypasses health technology assessment; litigants are predominantly higher socioeconomic status individuals with legal capital; reverse Robin Hood effect diverts public funds from primary oncology services; institutional bankruptcy risk | Justice; equity; non-maleficence at population level; sustainability | Judicialization of trastuzumab, bevacizumab, and checkpoint inhibitors in Brazil and Colombia; diversion of funds from HPV vaccination and basic screening programs | Frugal precision oncology paradigm; strengthening of HTA processes incorporating ethical values; legal frameworks distinguishing individual rights from systemic equity obligations |
CML: chronic myeloid leukemia; ESMO-MCBS: European Society for Medical Oncology Magnitude of Clinical Benefit Scale; HTA: health technology assessment; LMIC: low- and middle-income country; NGS: next-generation sequencing; NSCLC: non-small cell lung cancer; PTA: post-trial access.